Hong Kong University of Science and Technology Ye Yuru team developed a simple blood test to detect Alzheimer's disease early

The Hong Kong University of Science and Technology announced on the 28th that an international research team led by the school has successfully developed a simple and reliable blood test method that can screen and identify patients with Alzheimer's disease as early as possible with an accuracy rate of over 96%
.

Screening

The Hong Kong University of Science and Technology press release stated that the current diagnosis of AD patients by doctors mainly relies on the cognitive ability tests of the patients.
As for the pathological assessment of AD, the most commonly used medical procedures are brain imaging and lumbar puncture.
Brain lesions caused by AD
.

However, the related methods are expensive, invasive, and difficult to be widely used all over the world

Now, the research team led by Prof.
Ye Yuru, Vice President (Research and Development) of the University of Science and Technology, has identified 19 plasma protein biomarker groups with AD disease characteristics from 429 AD-related plasma proteins
.

Based on this set of markers, the team designed a scoring system that can distinguish AD patients from healthy people with an accuracy rate of over 96%

The 19 plasma protein biomarker groups identified by the research team (yellow dots in the picture) have the characteristics of AD, which are different from healthy people

The 19 plasma protein biomarker groups identified by the research team (yellow dots in the picture) have the characteristics of AD, which are different from healthy people

HKUST cooperated with the research team of University College London in the United Kingdom and clinicians such as the Prince of Wales Hospital and Queen Elizabeth Hospital in Hong Kong to collect plasma samples from Hong Kong patients with Alzheimer's disease and detect changes in the levels of more than 1,000 proteins
.

Professor Ye Yuru and his team used Chinese patient data to successfully develop the first blood test method that can screen and identify patients with Alzheimer's disease as early as possible, with an accuracy rate of over 96%
.

Professor Ye Yuru and his team used Chinese patient data to successfully develop the first blood test method that can screen and identify patients with Alzheimer's disease as early as possible, with an accuracy rate of over 96%
.

Under the leadership of Ye Yuru, the vice president of the University of Science and Technology and the director of the State Key Laboratory of Molecular Neuroscience, the research team identified 19 plasma proteins with characteristics of Alzheimer's disease from 429 types of plasma proteins related to Alzheimer's disease.
For the biomarker group, a scoring system was then designed to distinguish Alzheimer's disease patients from healthy people with an accuracy rate of over 96%
.

The system can also distinguish the three stages of Alzheimer's disease in the early, middle and late stages, and can be used to monitor the development of the patient's condition

Under the leadership of Ye Yuru, the vice president of the University of Science and Technology and the director of the State Key Laboratory of Molecular Neuroscience, the research team identified 19 plasma proteins with characteristics of Alzheimer's disease from 429 types of plasma proteins related to Alzheimer's disease.

The research results were recently published in the international authoritative scientific journal (Alzheimer's & Dementia: The Journal of the Alzheimer's Association) "Alzheimer's Disease and Dementia: Journal of the Alzheimer's Disease Patient Association"

According to statistics, the number of people suffering from AD in the world has exceeded 50 million

Last year, "The Lancet Public Health" published an online study on dementia among people over 60 years old in China.

The study found that the prevalence of dementia among adults aged 60 and over in China is 6.

The discovery of Professor Ye Yuru's team will be conducive to the early detection of Alzheimer's disease, and the prevention and treatment is of positive significance

Reference materials:

Jiang Y, Zhou X, Ip FC, et al.

The Y jiang, Zhou X-, the FC Ip, et Plasma proteomic Al Large-Scale Profiling Identifies Biomarker Panel A High-Performance Screening and for the staging of Alzheimer s disease apos.
.
Of Alzheimer & apos Dementia 2021.
DOI:.
10.
1002 / alz.
12369 in this message